Form 4: BioXcel Therapeutics Executive Javier Rodriguez Reports Routine Stock Acquisitions from RSU Vesting

Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, Inc., reported the acquisition of 68 shares of common stock through the vesting of Restricted Stock Units on June 14 and June 15, 2025, increasing his direct beneficial ownership to 1,659 shares.

Summary

• Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc. (BTAI), reported changes in his beneficial ownership via an SEC Form 4 filing.
• On June 14, 2025, Mr. Rodriguez acquired 33 shares of BioXcel Therapeutics Common Stock through the vesting of Restricted Stock Units (RSUs).
• Following this transaction, his direct beneficial ownership of Common Stock increased to 1,624 shares.
• On June 15, 2025, Mr. Rodriguez acquired an additional 35 shares of BioXcel Therapeutics Common Stock, also through the vesting of RSUs.
• After both reported transactions, Mr. Rodriguez's direct beneficial ownership of Common Stock stands at 1,659 shares.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The 33 RSUs vested on June 14, 2025, were part of a grant of 521 RSUs made on March 14, 2022, which vest 25% on the first anniversary and 6.25% at the end of each successive three-month period thereafter.
• The 35 RSUs vested on June 15, 2025, were part of a grant of 562 RSUs made on March 15, 2023, with a similar vesting schedule of 25% on the first anniversary and 6.25% quarterly thereafter.
• Mr. Rodriguez continues to hold 196 RSUs from the March 14, 2022 grant and 352 RSUs from the March 15, 2023 grant, subject to continuous employment.

Sentiment

Score: 6

Explanation: The document reports routine insider stock acquisitions through RSU vesting, which is a neutral to slightly positive event as it indicates an executive's continued equity stake in the company, aligning interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The acquisition of shares by a key executive, Javier Rodriguez, through RSU vesting demonstrates his continued equity stake in BioXcel Therapeutics, aligning his interests with those of shareholders.
• The transactions are a result of routine equity compensation, which is a standard practice to incentivize and retain management.

Future Outlook

The document indicates future vesting of remaining Restricted Stock Units (RSUs) for Javier Rodriguez, subject to his continuous employment. The RSUs granted on March 14, 2022, vest at 6.25% every three months after the first anniversary, and those granted on March 15, 2023, follow a similar quarterly vesting schedule.

Management Comments

• Javier Rodriguez holds the titles of Chief Legal Officer, Senior Vice President, and Corporate Secretary at BioXcel Therapeutics, Inc.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like BioXcel Therapeutics, where equity compensation such as Restricted Stock Units (RSUs) is a standard practice to incentivize and retain key executives.

Comparison to Industry Standards

• This type of RSU vesting and subsequent stock acquisition is a standard practice for executive compensation across the biotechnology and pharmaceutical industries.
• It aligns executive incentives with shareholder value creation, similar to compensation structures seen at companies like Moderna, Pfizer, or Amgen, where equity awards are a significant component of executive pay.
• No specific comparable projects or results are applicable to this type of filing, as it pertains to individual executive compensation rather than company performance metrics.

Stakeholder Impact

• Shareholders: The transactions demonstrate continued equity ownership by a key executive, potentially signaling alignment of interests and confidence in the company's long-term performance.
• Employees: The RSU vesting highlights the company's use of equity compensation, which is a common incentive for employee retention and motivation.

Next Steps

• Continued vesting of the remaining 196 RSUs from the March 14, 2022 grant, at a rate of 6.25% every three months, subject to continuous employment.
• Continued vesting of the remaining 352 RSUs from the March 15, 2023 grant, at a rate of 6.25% every three months, subject to continuous employment.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Javier Rodriguez, SEC Form 4, insider trading, stock acquisition, Restricted Stock Units, RSU vesting, common stock, beneficial ownership, corporate officer, equity compensation